You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

177Lu-PSMA I

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Prostate Cancer, Metastatic Cancer Trial (177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended

Not yet recruiting
  • Cancer
  • +3 more
  • 177Lu-PSMA-I&T - escalating renal absorbed dose
  • 177Lu-PSMA-I&T - recommended phase 2 regime
  • (no location specified)
Jun 14, 2023

High Grade Glioma Trial (177Lu-PSMA I&T)

Not yet recruiting
  • High Grade Glioma
  • 177Lu-PSMA I&T
  • (no location specified)
Dec 1, 2022

Cancer Trial in Meldola, Cesena ([177Lu]Lu-PSMA I&T)

Not yet recruiting
  • Cancer
  • [177Lu]Lu-PSMA I&T
  • Meldola, Forlì, Italy
  • +1 more
May 10, 2023

Prostate Cancer Trial ([177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy)

Not yet recruiting
  • Prostate Cancer
  • [177Lu]Lu-PSMA I&T
  • Stereotactic Radiotherapy
  • (no location specified)
May 30, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • With Positive PSMA Expression at Tumor Sites
  • 177Lu-PSMA-1 (radiopharmaceutical)
  • (no location specified)
Sep 26, 2023

Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)

Recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • 225^Ac-PSMA-617
  • 68^Ga-PSMA-11
  • Darlinghurst, Australia
  • +1 more
Nov 23, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in San

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +6 more
  • San Francisco, California
    University of California, San Francisco
Sep 8, 2022

Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma Trial in Los Angeles (drug,

Not yet recruiting
  • Oligometastatic Prostate Carcinoma
  • +3 more
  • Lutetium Lu-177 PNT2002
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Aug 15, 2022

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer Trial in

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • Vancouver, British Columbia, Canada
    BC Cancer
Nov 28, 2022

Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)

Not yet recruiting
  • Prostatic Neoplasms
  • Castration-Resistant
  • (no location specified)
Dec 1, 2022

Prostate Cancer Trial in New Orleans, New York (177Lu-PSMA-617, 68Ga-PSMA-HBED-CC)

Active, not recruiting
  • Prostate Cancer
  • New Orleans, Louisiana
  • +1 more
Nov 20, 2021

Prostate Cancer Trial in New York (177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC)

Terminated
Has Results
  • Prostate Cancer
  • New York, New York
    Weill Cornell Medical College
Jul 29, 2021

Prostate Cancer Trial (AAA617)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Mar 27, 2023

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 2, 2023

Metastatic Prostate Cancer Trial in Nanjing (177Lu-PSMA-0057)

Recruiting
  • Metastatic Prostate Cancer
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Sep 17, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Atlanta (procedure, radiation, other, drug)

Not yet recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Biospecimen Collection
  • +6 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 25, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 23, 2023

Oligometastatic Prostate Cancer (OMPC) Trial (AAA617)

Not yet recruiting
  • Oligometastatic Prostate Cancer (OMPC)
  • (no location specified)
Jul 3, 2023

Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer Trial in Melbourne (Lutetium-177 PSMA-I&T, Radium-223)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Sep 26, 2022

Oligometastatic Prostate Cancer Trial (177Lu-PSMA)

Not yet recruiting
  • Oligometastatic Prostate Cancer
  • (no location specified)
Sep 26, 2022

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022